Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models
Name
Sustained, Low-Dose Intraperitoneal Cisplatin Improves Treatment Outcome in Ovarian Cancer Mouse Models.pdf
Size
6.91 MB
Format
Adobe PDF
Checksum (MD5)
6c9962a2d3b7242cc67838ad8aaac8b8
Author(s)
Na, Young Jeong
Fulci, Giulia
del Carmen, Marcela G.
Birrer, Michael J.
Ye, Hongye
Tanenbaum, Laura Melanie
Mantzavinou, Aikaterini
Cima, Michael J.
Date Issued
November 2015
Journal
Journal of Controlled Release
Publisher
Elsevier
Citation
Ye, Hongye et al. “Sustained, Low-Dose Intraperitoneal Cisplatin Improves Treatment Outcome in Ovarian Cancer Mouse Models.” Journal of Controlled Release 220 (2015): 358–367.
Version
Author's final manuscript
Abstract
Intraperitoneal (IP) chemotherapy for ovarian cancer treatment prolongs overall survival by 16 months compared to intravenous chemotherapy but is not widely practiced due to catheter-related complications and complexity of administration. An implantable, nonresorbable IP microdevice was used to release chemotherapeutic agent at a constant rate of approximately 1.3 μg/h in vitro and 1.0 μg/h in vivo. Studies conducted in two orthotopic murine models bearing human xenografts (SKOV3 and UCI101) demonstrate that continuous dosing reduces tumor burden to the same extent as weekly IP bolus drug injections. Treatment-induced toxicity was quantified via body weight loss and complete blood count. The microdevice resulted in significantly less toxicity than IP bolus injections, despite administration of higher cumulative doses (total area under the concentration-time curve of 3049 ng day/mL with the microdevice vs. 2118 ng-day/mL with IP bolus injections). This preclinical study supports the concept that reduced toxicity with similar efficacy outcomes can be achieved by continuous dosing in ovarian cancer patients currently treated with IP therapy.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.jconrel.2015.11.001
